Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Palliative Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kirkham, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kirkham, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

The palliation of cerebral tumours with high-dose dexamethasone: a review

SR Kirkham

Medical Director, Pilgrims' Hospice, Canterbury

The historical use of corticosteroids for cerebral oedema due to malignancy is reviewed. The mechanisms for the formation and treatment of cerebral oedema are discussed and advice is given as to the clinical use of dexamethasone, including mention of adverse effects and drug interactions.

Key Words: brain neoplasms • brain oedema • dexomethasone • drug toxicity • glucocorticoids • palliative treatment

Palliative Medicine, Vol. 2, No. 1, 27-33 (1988)
DOI: 10.1177/026921638800200105
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?